Učitavanje...
AT-06 A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
BACKGROUND: Preclinical studies indicated that inhibition of NF-kB with bortezemib markedly enhance tamoxifen-mediated glioma apoptosis. A potentially synergistic cytotoxic effect of the combination may benefit patients with malignant gliomas. METHODS: We conducted single institution phase II trial...
Spremljeno u:
| Izdano u: | Neuro Oncol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4217841/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.6 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|